Royal Pharmaceutical Society warns on nasal sprays
Analysis based on 7 articles · First reported Jan 08, 2026 · Last updated Jan 09, 2026
This event is unlikely to have a direct significant impact on financial markets, but it could subtly influence consumer behavior regarding over-the-counter cold and allergy medications. Pharmaceutical companies producing nasal decongestants might face pressure to update product packaging with clearer warnings, potentially incurring minor costs or affecting sales if consumers reduce usage.
The KC Pharmaceuticals has issued new advice urging people to limit the use of nasal decongestant sprays to a maximum of seven days. This warning comes after a survey revealed that a significant number of pharmacists believe the public is unaware of the risks associated with prolonged use, specifically 'rebound congestion' or rhinitis medicamentosa, which can worsen symptoms and lead to dependency. Professor Amira Guirguis, chief scientist at the KC Pharmaceuticals, emphasized the need for clearer warnings on packaging and greater public awareness. The advice is particularly relevant as the United Kingdom — National Health Service faces increased strain from winter viruses like flu, Covid, and norovirus, which often cause blocked noses.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard